# A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Study · id `cardio:ct-nct03683186` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03683186](<https://clinicaltrials.gov/study/NCT03683186>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03683186

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 1000 participants.

## Technical summary

Registry record NCT03683186. Allocation not applicable; no masking; primary purpose treatment. Start 2019-09-23 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1000 participants (planned count; ClinicalTrials.gov record NCT03683186, source copy `cardio:ctgov-nct03683186-2026-10-06`, retrieved 2026-10-31)
- Started: 2019-09-23 (actual) (ClinicalTrials.gov record NCT03683186, source copy `cardio:ctgov-nct03683186-2026-10-06`, retrieved 2026-10-31)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT03683186, source copy `cardio:ctgov-nct03683186-2026-10-06`, retrieved 2026-10-31)
- Completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT03683186, source copy `cardio:ctgov-nct03683186-2026-10-06`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Croatia; Czechia; Denmark; France; Germany; Greece; Hungary; Israel; Italy; Mexico; Netherlands; Poland; Portugal; Romania; Serbia; Singapore; South Korea; Spain; Sweden; Taiwan; Türkiye; Ukraine; United Kingdom (ClinicalTrials.gov record NCT03683186, source copy `cardio:ctgov-nct03683186-2026-10-06`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03683186-2026-10-06`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
- Condition: PAH
- Condition: Pulmonary Hypertension
- Condition: Pulmonary Arterial Hypertension
- Condition: Hypertension
- Condition: Connective Tissue Diseases
- Condition: Familial Primary Pulmonary Hypertension
- Condition: Vascular Diseases
- Condition: Cardiovascular Diseases
- Condition: Hypertension, Pulmonary
- Condition: Lung Diseases
- Condition: Respiratory Tract Disease
- Intervention (Drug): Ralinepag
- Lead sponsor: United Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: United Therapeutics (`cardio:org-united-therapeutics`)

## Provenance

Content hash: 794df791e0628041ff56082641067824af5c4d96cc7e2ac9c5bd44e5c3c7bd85
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
